Buserelin
Also known as: Buserelin acetate, D-Ser(tBu)6-des-Gly10-GnRH-ethylamide, Ferring 3611, HOE-766, Profact, Receptal, Suprefact
Source Buserelin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Buserelin is a synthetic nonapeptide analogue of gonadotropin‑releasing hormone (GnRH) that functions as a GnRH agonist. It is an approved prescription drug administered by implant, subcutaneous injection, intranasal spray or intravenous infusion. By creating a reversible hypogonadal state, it is used in hormone‑dependent conditions such as prostate and premenopausal breast cancers, endometriosis, central precocious puberty, and as a pretreatment in assisted reproduction. Veterinary applications include induction of estrus in bitches.
Mechanism of Action
Buserelin binds to the pituitary GnRH receptor, initially provoking a surge of luteinising hormone (LH) and follicle‑stimulating hormone (FSH). Repeated exposure leads to receptor desensitisation and down‑regulation, suppressing LH/FSH secretion. The resulting decline in gonadal steroid production (estrogen or testosterone) produces a reversible hypo‑gonadal state, which underlies its therapeutic effects in hormone‑dependent diseases.
What the Research Shows
Clinical reviews report that GnRH analogues, including buserelin, relieve pain in endometriosis and improve pregnancy rates, though they are linked with higher adverse‑event rates. A 1990 review describes buserelin’s comparable efficacy to orchidectomy in hormone‑sensitive prostate cancer and its utility in premenopausal breast cancer, uterine leiomyoma, central precocious puberty, and infertility protocols. Veterinary literature cites buserelin among GnRH agonists used for estrus induction in dogs, noting variable efficacy. Case reports suggest benefit in hidradenitis suppurativa, while animal studies report enteric neurodegeneration and gastrointestinal dysmotility after prolonged exposure. Overall, evidence supports short‑term hormonal suppression, but long‑term safety data remain limited.
Reported Benefits
Evidence shows buserelin can effectively suppress gonadal hormone production, providing pain relief in endometriosis and facilitating assisted reproduction. In prostate cancer, it offers efficacy comparable to surgical orchidectomy with fewer adverse effects. It is useful in central precocious puberty and may reduce uterine fibroid size pre‑surgery. Veterinary use demonstrates its role in inducing estrus in bitches, expanding reproductive management options. Overall, the drug delivers reversible hormonal control across multiple sex‑hormone‑dependent conditions.
Limitations of the Evidence
Efficacy in canine estrus induction varies and its practical applicability is uncertain. Long‑term data on bone mineral density and potential gastrointestinal dysmotility, observed in animal models, are lacking. The cost of GnRH agonists may limit widespread use, and large‑scale randomized trials are still needed to confirm benefits in conditions such as hidradenitis suppurativa. Benefits in uterine leiomyoma are based on preliminary data and do not replace surgical intervention.
Safety Considerations
Buserelin commonly produces hypo‑estrogenic symptoms such as hot flushes, vaginal dryness and reduced libido, which are generally well tolerated. Fertility typically returns after discontinuation. No adverse effects on lipid metabolism have been reported, but the impact on bone mineral content with prolonged therapy remains unclear. Gastrointestinal dysmotility and enteric neuronal changes have been noted in animal studies and in patients with antibodies to GnRH, suggesting a need for monitoring in susceptible individuals. Overall, the adverse‑event profile is considered favourable compared with surgical or high‑dose estrogen approaches.
How It Is Administered
Buserelin is available as an implant, subcutaneous injection, intranasal spray, and intravenous formulation. In clinical practice, intermittent subcutaneous or intranasal dosing is used to achieve pituitary desensitisation, while implants provide sustained release over weeks to months. The choice of route depends on the indication and patient preference.
Routes of Administration
Goals & Uses
- Controlled ovarian stimulation / ARTReproductive MedicineHigh
- Induction of ovulation for IVFReproductiveHigh
- Precocious pubertyPediatric EndocrinologyModerate
- Prostate cancer treatment (androgen deprivation)OncologyHigh
- Management of endometriosisGynecologyModerate
- Uterine fibroids (leiomyomata)GynecologyHigh
- Androgen suppression in prostate cancerOncologyModerate
- Endometriosis managementGynecologyHigh
- Gender-affirming hormone therapy (puberty suppression)EndocrinologyModerate
Contraindications
- Hypersensitivity to GnRH or analoguesImmunologicalHigh
- Severe hepatic impairmentOrganModerateLiver function concerns
- Osteoporosis (pre-existing severe)MusculoskeletalModerate
- Undiagnosed vaginal bleedingGynecologicalHigh
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Breast cancer (estrogen‑dependent)OncologyHigh
- BreastfeedingPopulationModeratePotential transfer into breast milk or insufficient safety data
Adverse Effects
- Hot flushes / vasomotor symptomsEndocrine/VasomotorCommon
- Injection site reactionsLocalCommon
- Injection site painLocalCommonPain at the injection site
- HeadacheNeurologicCommonPain in the head or upper neck
- Decreased bone mineral densityMusculoskeletalCommon
- Hot flashesEndocrine / VasomotorCommon
- Mood changes / depressionPsychiatricUncommon
- Sexual dysfunction / loss of libidoSexual HealthCommon
- NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
- Tumor flare (prostate cancer)OncologicalUncommon
Drug Interactions
- Estrogen‑containing contraceptivesModerate
- Gonadotropins (FSH/LH preparations)Low
- CYP3A4 inhibitors (e.g., ketoconazole)Low
- Insulin / antidiabetic agentsModerate
- QT-prolonging agentsModerate
- Anti-androgens (e.g., flutamide, bicalutamide)Low
Population Constraints
- Patients with depression or psychiatric historyPsychiatricRelative
- Elderly patients with cardiovascular diseaseCardiovascularRelative
- Pediatric patientsAgeRelative
- Elderly (>75 years)GeriatricRelative
- Patients with osteopenia/osteoporosisMusculoskeletalRelative
- Pediatric use (prepubertal / early pubertal)AgeRelative
Regulatory Status
- European UnionApprovedApproved: infertility treatment, prostate cancer, endometriosisMarketed under brand Suprefact.
- United StatesUnapprovedNot FDA‑approved; used off‑label in clinical trials.
- United KingdomApprovedApproved: infertility, prostate cancerAvailable via specialist prescription.
Approved in the EU, UK and many non‑US markets; not FDA‑approved in the United States.
Evidence & Sources
- Journal ArticleModerateKutzler MA2005-01-01T00:00:00.000000Z
- Journal ArticleModerateHipkin LJ1992-01-01T00:00:00.000000Z
- Journal ArticleModerateBrown J, Farquhar C2015-01-01T00:00:00.000000Z
- Journal ArticleHighMasson R, et al.2023-01-01T00:00:00.000000Z
- Journal ArticleModerateOhlsson B2017-01-01T00:00:00.000000Z
- Journal ArticleModerateBrogden RN, Buckley MM, Ward A1990-01-01T00:00:00.000000Z
Frequently Asked Questions
How does buserelin differ from the body's natural GnRH?
Buserelin is a synthetic peptide that binds the same pituitary GnRH receptor but is more resistant to enzymatic breakdown. A single dose mimics the natural hormone’s surge, while repeated dosing causes receptor desensitisation, leading to prolonged suppression of LH and FSH.
What medical conditions is buserelin used to treat?
Clinical reports cite its use for hormone‑sensitive prostate and premenopausal breast cancers, endometriosis, central precocious puberty, as a pretreatment in assisted reproduction, and for inducing estrus in female dogs. It is also investigated for uterine fibroids and certain skin disorders.
What are the most common side effects?
The drug commonly causes hypo‑estrogenic symptoms such as hot flushes, vaginal dryness and decreased libido. Fertility usually returns after stopping therapy. Rarely, gastrointestinal dysmotility has been observed in animal models and in patients with anti‑GnRH antibodies.
Is the hormonal suppression caused by buserelin permanent?
No. Repeated dosing leads to reversible pituitary desensitisation; once the drug is stopped, LH and FSH levels recover and normal gonadal function usually resumes, allowing return of fertility.
Can buserelin be used in men with prostate cancer?
A 1990 review reports that buserelin provides comparable efficacy to orchidectomy in hormone‑sensitive prostate cancer, offering a medical alternative to surgical castration with a lower incidence of adverse effects.
What is Buserelin?
Buserelin is a synthetic nonapeptide analogue of gonadotropin‑releasing hormone (GnRH) that functions as a GnRH agonist. It is an approved prescription drug administered by implant, subcutaneous injection, intranasal spray or intravenous infusion. By creating a reversible hypogonadal state, it is used in hormone‑dependent conditions such as prostate and premenopausal breast cancers, endometriosis, central precocious puberty, and as a pretreatment in assisted reproduction. Veterinary applications include induction of estrus in bitches.
What is Buserelin used for?
Buserelin is educationally associated with: Controlled ovarian stimulation / ART, Induction of ovulation for IVF, Precocious puberty, Prostate cancer treatment (androgen deprivation), Management of endometriosis, Uterine fibroids (leiomyomata), Androgen suppression in prostate cancer, Endometriosis management, Gender-affirming hormone therapy (puberty suppression). Educational only — not medical advice.
How is Buserelin administered?
Recorded routes of administration: Implant, Intramuscular, Intranasal, Intravenous, Nasal, Subcutaneous.
What are the potential side effects of Buserelin?
Reported adverse effects include: Hot flushes / vasomotor symptoms, Injection site reactions, Injection site pain, Headache, Decreased bone mineral density, Hot flashes, Mood changes / depression, Sexual dysfunction / loss of libido, Nausea, Tumor flare (prostate cancer). This list is not exhaustive — consult a qualified clinician.
Who should avoid Buserelin?
Recorded contraindications: Hypersensitivity to GnRH or analogues, Severe hepatic impairment, Osteoporosis (pre-existing severe), Undiagnosed vaginal bleeding, Pregnancy, Breast cancer (estrogen‑dependent), Breastfeeding. Consult a qualified clinician before use.